Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan

Keyphrases

• Pediatric 100%
• BCP-ALL 100%
• Japan 100%
• Philadelphia Chromosome-negative 100%
• Kinase Fusion 100%
• Tyrosine Kinase Inhibitor 66%
• Age of Onset 66%
• CRLF2 66%
• ABL1 66%
• PDGFRB Rearrangement 66%
• Working Diagnosis 33%
• Standard Risk 33%
• Minimal Residual Disease 33%
• Clinical High Risk 33%
• Disease-based 33%
• Old Age 33%
• High Risk 33%
• Overall Survival Rate 33%
• Event-free Survival 33%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 33%
• Leukemia Patients 33%
• Genetic Abnormalities 33%
• IKZF1 Deletion 33%
• Janus Kinase 2 (JAK2) 33%
• White Blood Cell Count 33%
• Transcriptome Analysis 33%
• Genetic Analysis 33%
• Male Predominance 33%
• Cytokine Receptor 33%
• Tyrosine Kinase Receptor 33%
• Platelet-derived Growth factor-BB (PDGF-BB) 33%
• National Cancer Institute 33%
• Conventional Chemotherapy 33%
• Multiplex 33%
• Female-to-male 33%
• NCoR1 33%
• JAK2 Rearrangement 33%

Medicine and Dentistry

• Pediatrics 100%
• B Cell 100%
• Acute Lymphoblastic Leukemia 100%
• Precursor 100%
• Phosphotransferase 100%
• Tyrosine-Kinase Inhibitor 66%
• Onset Age 66%
• Janus Kinase 66%
• Malignant Neoplasm 33%
• Minimal Residual Disease 33%
• Event Free Survival 33%
• Survival Rate 33%
• Overall Survival 33%
• Gene Expression Profiling 33%
• Allogeneic Hematopoietic Stem Cell Transplantation 33%
• Cell Count 33%
• Leukocyte 33%
• Genetic Analysis 33%
• Tyrosine Kinase Receptor 33%
• Cytokine Receptor 33%
• Chemotherapy 33%

Biochemistry, Genetics and Molecular Biology

• B Cell 100%
• Precursor 100%
• Kinase 100%
• Phosphotransferase 100%
• Platelet Derived Growth Factor Receptor Beta 100%
• Genetics 66%
• Tyrosine Kinase Inhibitor 66%
• Janus Kinase 66%
• CRLF2 66%
• Overall Survival 33%
• Gene Expression Profiling 33%
• Event Free Survival 33%
• IKZF1 33%
• Survival Rate 33%
• Allogeneic Hematopoietic Stem Cell Transplantation 33%
• Leukocyte Count 33%
• Cytokine Receptor 33%
• Tyrosine Kinase Receptor 33%
• Last Year Needle 33%